NCT07198633View on ClinicalTrials.gov

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Advanced Prostate Cancer
Interventions
DRUG

QLC5508

B7H3 ADC; QLC5508 will be administered by injection at the dose and dosing frequency specified in the protocol.

DRUG

abiraterone acetate

An oral CYP17 inhibitor; abiraterone acetate will be administered orally at the dose and dosing frequency specified in the protocol

DRUG

enzalutamide

An oral androgen receptor inhibitor; enzalutamide will be administered orally at the dose and dosing frequency specified in the protocol.

DRUG

QLH12016

An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT07198633 - A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter